These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31196258)

  • 1. Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma.
    Li S; Xu Q; Zhao L; Ye C; Hua L; Liang J; Yu R; Liu H
    J Nanosci Nanotechnol; 2019 Dec; 19(12):7539-7545. PubMed ID: 31196258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy.
    Zong Z; Hua L; Wang Z; Xu H; Ye C; Pan B; Zhao Z; Zhang L; Lu J; Mei LH; Rutong Y
    Drug Deliv; 2019 Dec; 26(1):34-44. PubMed ID: 30744436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Hypoxic Radiosensitizer-Prodrug Liposome Delivery DNA Repair Inhibitor Dbait Combination with Radiotherapy for Glioma Therapy.
    Liu H; Cai Y; Zhang Y; Xie Y; Qiu H; Hua L; Liu X; Li Y; Lu J; Zhang L; Yu R
    Adv Healthc Mater; 2017 Jun; 6(12):. PubMed ID: 28371526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
    Uram Ł; Markowicz J; Misiorek M; Filipowicz-Rachwał A; Wołowiec S; Wałajtys-Rode E
    Eur J Pharm Sci; 2020 Sep; 152():105439. PubMed ID: 32615261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
    Song S; Mao G; Du J; Zhu X
    Drug Deliv; 2016 May; 23(4):1404-8. PubMed ID: 26203687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
    Mao J; Meng X; Zhao C; Yang Y; Liu G
    Anticancer Drugs; 2019 Jul; 30(6):604-610. PubMed ID: 30855310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tumor microenvironment-responsive micelle co-delivered radiosensitizer Dbait and doxorubicin for the collaborative chemo-radiotherapy of glioblastoma.
    Zhang S; Jiao X; Heger M; Gao S; He M; Xu N; Zhang J; Zhang M; Yu Y; Ding B; Ding X
    Drug Deliv; 2022 Aug; 29(1):2658-2670. PubMed ID: 35975300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy.
    Kadhim ZA; Sulaiman GM; Al-Shammari AM; Khan RA; Al Rugaie O; Mohammed HA
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy.
    Hua L; Wang Z; Zhao L; Mao H; Wang G; Zhang K; Liu X; Wu D; Zheng Y; Lu J; Yu R; Liu H
    Theranostics; 2018; 8(18):5088-5105. PubMed ID: 30429888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
    Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T
    Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
    Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
    Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
    Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
    Lesueur P; Lequesne J; Grellard JM; Dugué A; Coquan E; Brachet PE; Geffrelot J; Kao W; Emery E; Berro DH; Castera L; Goardon N; Lacroix J; Lange M; Capel A; Leconte A; Andre B; Léger A; Lelaidier A; Clarisse B; Stefan D
    BMC Cancer; 2019 Mar; 19(1):198. PubMed ID: 30832617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
    He Y; Kaina B
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.